Results from VIITAL: A phase 3, randomized, intrapatient-controlled trial of an investigational collagen type VII gene-corrected autologous cell therapy, EB-101, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB) Tang, J. Y., Marinkovich, M. P., Wiss, K., McCarthy, D., Truesdale, A., Chiou, A. S., McIntyre, J. K., Moore, A., Grachev, I. ELSEVIER SCIENCE INC. 2023: S138

View details for Web of Science ID 001037960301053